Stocks · Health care · Pharmaceutical Preparations

LIGAND PHARMACEUTICALS INC

LGND Clue Score50
United States Fiscal year ends December CIK 0000886163 Results filed 29 Oct 2026

What the insiders did Net selling

Insider
Date
Role
Action
Shares
Price
Amount
Octavio Espinoza
27 May 2026
Chief Financial Officer
Exercised, kept
972
$52.84
$51.36K
Octavio Espinoza
27 May 2026
Chief Financial Officer
Exercised, kept
764
$63.62
$48.61K
Octavio Espinoza
16 Dec 2025
Chief Financial Officer
Exercised, kept
181
$103.42
$18.72K
Octavio Espinoza
16 Dec 2025
Chief Financial Officer
Exercised, kept
652
$92.65
$60.41K
Octavio Espinoza
16 Dec 2025
Chief Financial Officer
Exercised, kept
285
$63.62
$18.13K
Octavio Espinoza
16 Dec 2025
Chief Financial Officer
Exercised, kept
69
$57.22
$3.95K
Octavio Espinoza
16 Dec 2025
Chief Financial Officer
Exercised, kept
1,194
$52.84
$63.09K
Jason Aryeh
8 Dec 2025
Director
Exercised, kept
2,034
$69.51
$141.38K

What was left out

Form 4 filings counted 52
Amendments (4/A) skipped 0
Filings about a different issuer 2
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 38
Sales straight out of an exercise 93
Sales at will 15
Transactions with no price 0
Shares from compensation/vesting 281,927
History held since 29 Sep 2006